UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Journal of hematology and oncology, 2016-08, Vol.9 (1), p.73-11, Article 73

2016

Volltextzugriff (PDF)

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (17), p.6899-6905

2009

Volltextzugriff (PDF)

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Clinical cancer research, 2020-01, Vol.26 (1), p.54-60

2020

Volltextzugriff (PDF)

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (23), p.5344-5354

2020

Volltextzugriff (PDF)

Abstract 289: Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.289-289

2016

Volltextzugriff (PDF)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Oncotarget, 2016-11, Vol.7 (48), p.78896-78909

2016

Volltextzugriff (PDF)

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Clinical cancer research, 2011-12, Vol.17 (24), p.7743-7753

2011

Volltextzugriff (PDF)

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

Cancer research (Chicago, Ill.), 2020-10, Vol.80 (23), p.5344-5354

2020

Volltextzugriff (PDF)

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Blood, 2017-12, Vol.130, p.3095-3095

2017

Volltextzugriff (PDF)

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.4032-4032

2012

Volltextzugriff (PDF)

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.3299-3299

2016

Volltextzugriff (PDF)

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Blood, 2016-12, Vol.128 (22), p.5662-5662

2016

Volltextzugriff (PDF)

Abstract 1771: KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1771-1771

2012

Volltextzugriff (PDF)

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.1818-1818

2015

Volltextzugriff (PDF)

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Blood, 2015-12, Vol.126 (23), p.3048-3048

2015

Volltextzugriff (PDF)

Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4434-4434

2015

Volltextzugriff (PDF)

Abstract 2066: Combination therapy of human multiple myeloma using proteosome and CRM1 inhibitors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2066-2066

2013

Volltextzugriff (PDF)

Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1772-1772

2014

Volltextzugriff (PDF)

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.2084-2084

2014

Volltextzugriff (PDF)

Targeting The Nuclear Export Signal In Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.1925-1925

2013

Volltextzugriff (PDF)

Abstract 3513: MK-2206 combined with ridaforolimus or topoisomerase inhibitors synergistically impede the growth of sarcoma cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3513-3513

2011

Volltextzugriff (PDF)

Abstract B176: Novel inhibitors of nuclear export as a treatment for multiple myeloma

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B176-B176

2011

Volltextzugriff (PDF)

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Blood, 2010-11, Vol.116 (21), p.3006-3006

2010

Volltextzugriff (PDF)

Abstract 5403: Akt inhibitor MK-2206 combined with Dasatinib synergistically inhibits the growth of sarcoma cells

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5403-5403

2010

Volltextzugriff (PDF)

Abstract 725: Protein kinase-CK2 inhibition as a potential treatment for multiple myeloma

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.725-725

2010

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(43)
Reviews
(3)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer Research
(12)
Blood
(10)
Clinical Cancer Research
(4)
Sarcoma
(2)
Wasafiri
(2)
American Journal Of Human Genetics
(1)
American Journal Of Sociology
(1)
Anz Journal Of Surgery
(1)
Anz Journal Of Surgery/anz Journal Of Surgery
(1)
Autism
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma

Abstract 289: Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Abstract 1771: KOS-2464, a novel CRM1 inhibitor and a potential drug for multiple myeloma and leukemia

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma

Abstract 2066: Combination therapy of human multiple myeloma using proteosome and CRM1 inhibitors

Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Targeting The Nuclear Export Signal In Multiple Myeloma

Abstract 3513: MK-2206 combined with ridaforolimus or topoisomerase inhibitors synergistically impede the growth of sarcoma cells

Abstract B176: Novel inhibitors of nuclear export as a treatment for multiple myeloma

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Abstract 5403: Akt inhibitor MK-2206 combined with Dasatinib synergistically inhibits the growth of sarcoma cells

Abstract 725: Protein kinase-CK2 inhibition as a potential treatment for multiple myeloma

Suchergebnisse filtern